Aptargroup Stock Price, News & Analysis

AptarGroup (NYSE: ATR), a leader in drug and consumer product technologies, has achieved the prestigious 'A List' ranking on CDP's Climate Change Assessment for 2024. The recognition comes from the company's demonstrated efforts in emission reduction, climate risk mitigation, and advancement of the low-carbon economy.

Among 24,800 responding companies, Aptar stood out for its environmental initiatives, including:

• Setting science-based targets for Scope 1 and 2 emissions reductions aligned with 1.5°C warming limit by 2030
• Implementing renewable electricity targets and Scope 3 goals validated by Science Based Targets Initiative
• Securing Power Purchase Agreements in Europe and US for localized renewable energy
• Obtaining ISO 14046 certification for greenhouse gas emissions reduction

The CDP assessment, which evaluated data from companies representing over 142 trillion USD in assets, uses a comprehensive scoring system from A to D- based on environmental disclosure, risk management, and leadership practices.

AptarGroup (NYSE:ATR) reported strong Q4 2024 results with a 1% increase in reported sales to $848 million and a 62% increase in net income to $101 million. Core sales grew 2% despite negative currency effects. The company's pharma franchise achieved 8% sales growth for the full year 2024, while net income grew 32% to $375 million.

Q4 segment performance showed Aptar Pharma's core sales up 4%, Aptar Beauty's core sales down 3%, and Aptar Closures' core sales up 7%. The company reported Q4 earnings per share of $1.49, a 60% increase year-over-year. Full-year 2024 reported sales increased 3% to $3.58 billion, with adjusted earnings per share of $5.64, up 18% from the previous year.

For Q1 2025, Aptar expects earnings per share between $1.11 and $1.19, facing headwinds from foreign currencies and higher tax rates. The company also announced a $500 million share repurchase authorization and a quarterly dividend of $0.45 per share.

AptarGroup (NYSE: ATR) has announced its Board's declaration of a quarterly cash dividend of $0.45 per share, payable on February 26, 2025, to stockholders of record as of February 5, 2025. The company will host a conference call on February 7, 2025, at 8:00 a.m. Central Time to discuss Q4 and full-year 2024 results.

Additionally, Aptar has scheduled its 2025 Annual Meeting of Stockholders to be held virtually on May 7, 2025, at 9:00 a.m. Central Time. Shareholders of record as of March 14, 2025, will be eligible to vote at the meeting.

AptarGroup (NYSE: ATR) has been recognized as one of America's Most Responsible Companies 2025 by Newsweek, ranking 71st out of 600 U.S. companies. This marks the sixth consecutive year of this achievement.

The company, which specializes in drug and consumer product dosing, dispensing and protection technologies, has been acknowledged for its sustainability initiatives, including sourcing renewable energy, certifying sites as landfill-free, and developing more sustainable products that are recyclable, reusable, and refillable.

Aptar has also received recognition from Forbes as a World's Top Companies for Women and from TIME as one of the World's Most Sustainable Companies. As an active member of the Ellen MacArthur Foundation and the World Business Council for Sustainable Development, Aptar is working towards advancing circular economy initiatives.

The Newsweek ranking, conducted in partnership with Statista, evaluated the top 2,000 largest public U.S. companies based on ESG criteria and a perception study of 26,000 individuals, considering factors such as emissions, energy use, board diversity, and transparency.

AptarGroup (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has announced its 2025 quarterly conference call schedule. The company will host four earnings calls throughout the year, each beginning at 8:00 a.m. Central Time.

The schedule is as follows:

• Q4 and Annual 2024 Results: Press release on February 6, call on February 7
• Q1 2025 Results: Press release on May 1, call on May 2
• Q2 2025 Results: Press release on July 31, call on August 1
• Q3 2025 Results: Press release on October 30, call on October 31

Press releases will be issued after NYSE trading closes on the specified dates. Interested parties can access live webcasts through investors.aptar.com, where call replays will also be available. Each conference call is expected to last approximately one hour.

AptarGroup (NYSE: ATR), a leader in drug and consumer product dosing, dispensing and protection technologies, has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. Stephan Tanda, President and CEO, will deliver a presentation at 12:45 p.m. EST. Executive Vice President and CFO Vanessa Kanu and Aptar Pharma President Gael Touya will also be in attendance. The presentation materials will be accessible to investors through the company's website at www.aptar.com.

AptarGroup (NYSE: ATR) has been recognized among Forbes' 'World's Top Companies for Women 2024', ranking 41st out of 400 companies. This marks the fourth consecutive year of recognition for Aptar, highlighting their commitment to Inclusion, Equity and Belonging (IE&B). The company demonstrates strong female representation with 50% women on their Board of Directors and 37% women on their executive committee.

The ranking, conducted in partnership with Statista, evaluated companies across three categories: employer brand, public opinion, and leadership. The assessment involved surveying approximately 100,000 women from multinational corporations across 37 countries, focusing on companies operating in at least two continental regions.

AptarGroup (NYSE:ATR) reported strong Q3 2024 results with a 2% increase in both reported and core sales to $909 million. Net income rose 19% to $100 million, with earnings per share up 17% to $1.48. The Pharma segment led growth with 8% reported sales increase, while Closures grew 3% and Beauty declined 7%. The company achieved an adjusted EBITDA of $208 million, delivering a 23% margin. For Q4 2024, Aptar expects earnings per share between $1.22 and $1.30, targeting double-digit adjusted EPS growth for the full year.

AptarGroup, Inc. (NYSE: ATR) has been awarded a $4.8 million, five-year contract from the U.S. Federal Government to advance development of its ActivShield™ technology. This innovative solution sterilizes medical devices and instruments without a power source, making it suitable for rural areas, military settings, and healthcare facilities with sterilization capabilities.

ActivShield™ uses Aptar CSP Technologies' 3-Phase Activ-Polymer™ platform and emits controlled chlorine dioxide gas for sterilization. It offers advantages over conventional methods, including portability, no infrastructure requirements, and absence of health risks associated with Ethylene Oxide (EtO). The technology can be custom-engineered, is stable, compact, and manufactured in the United States.

This advancement could significantly reduce infection risks in remote or emergency response settings and decrease reliance on expensive and unsafe sterilization techniques. For the military, it can provide access to sterilized instruments in far-forward environments during critical pre-hospitalization periods.